Dexcom Inc.
DexCom Reports Strong Q2 2026 Financial Results and Raises Guidance
Summary
DexCom, Inc. reported a 13% year-over-year increase in revenue for the second quarter of 2026, reaching $1.308 billion. The company also announced positive results from the CONNECT trial and the launch of the Stelo app. DexCom raised its fiscal year 2026 revenue guidance to $5.18 - $5.25 billion, reflecting an approximate 11-13% growth. GAAP operating income was $318.3 million, and non-GAAP operating income was $328.3 million. Net income was $249.1 million, or $0.64 per diluted share, and non-GAAP net income was $269.1 million, or $0.70 per diluted share.
Profitelligence Alerts
Get alerts for DXCM
Be first to know when Dexcom Inc. files with the SEC.
Filing Categories
Advertisement
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Official SEC Documents
Advertisement